Evidence map›Paper›PMID 28754664›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2017

Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.

Paul C Pagano, Linh M Tran, Nawal Bendris, Sean O'Byrne, Henry T Tse, Shivani Sharma, Jonathan W Hoech, Stacy J Park, Elvira L Liclican, Zhe Jing and 13 more

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Notch Transduction in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Paul C PaganoDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Linh M TranDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Nawal BendrisDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, Texas.
Sean O'ByrneDepartment of Bioengineering, UCLA, Los Angeles, California.
Henry T TseDepartment of Bioengineering, UCLA, Los Angeles, California.
Shivani SharmaDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, California.
Jonathan W HoechDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Stacy J ParkDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Elvira L LiclicanDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Zhe JingDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Rui LiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Kostyantyn KrysanDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Manash K PaulDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Yari FontebassoDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Jill E LarsenQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Shaina HakimiDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Atsuko SekiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Michael C FishbeinDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
James K GimzewskiDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, California.
Dino Di CarloDepartment of Bioengineering, UCLA, Los Angeles, California.
John D MinnaHamon Center for Therapeutic Oncology Research and Departments of Medicine and Pharmacology, UT Southwestern Medical Center, Dallas, Texas.
Tonya C WalserDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Steven M DubinettDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California. sdubinett@mednet.ucla.edu.

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
The UCLA - Boston University Lung Cancer Biomarker Development LaboratoryU01CA152751 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M., ELASHOFF, DAVID · 2010 to 2015
$5.0M
Lung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8M
Inflammation in the pathogenesis of lung cancerI01BX000359 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI DUBINETT, STEVEN M. · 2009 to 2018
–
BLRD VA I01 BX000359NCATS NIH HHS UL1 TR000124NCI NIH HHS P50 CA070907NCI NIH HHS T32 CA009120NCI NIH HHS U01 CA152751NCI NIH HHS U01 CA176284
6 · The paper itself

Abstract

Lung cancers are documented to have remarkable intratumoral genetic heterogeneity. However, little is known about the heterogeneity of biophysical properties, such as cell motility, and its relationship to early disease pathogenesis and micrometastatic dissemination. In this study, we identified and selected a subpopulation of highly migratory premalignant airway epithelial cells that were observed to migrate through microscale constrictions at up to 100-fold the rate of the unselected immortalized epithelial cell lines. This enhanced migratory capacity was found to be Rac1-dependent and heritable, as evidenced by maintenance of the phenotype through multiple cell divisions continuing more than 8 weeks after selection. The morphology of this lung epithelial subpopulation was characterized by increased cell protrusion intensity. In a murine model of micrometastatic seeding and pulmonary colonization, the motility-selected premalignant cells exhibit both enhanced survival in short-term assays and enhanced outgrowth of premalignant lesions in longer-term assays, thus overcoming important aspects of "metastatic inefficiency." Overall, our findings indicate that among immortalized premalignant airway epithelial cell lines, subpopulations with heritable motility-related biophysical properties exist, and these may explain micrometastatic seeding occurring early in the pathogenesis of lung cancer. Understanding, targeting, and preventing these critical biophysical traits and their underlying molecular mechanisms may provide a new approach to prevent metastatic behavior.

Indexed as

AnimalsBronchiCell Line, TumorCell MovementCell ProliferationCell SurvivalEpithelial CellsGene Expression ProfilingHumansLung NeoplasmsMiceMice, Inbred NODrac1 GTP-Binding ProteinSpecific Pathogen-Free OrganismsXenograft Model Antitumor Assaysrac1 GTP-Binding ProteinRAC1 protein, human

Identifiers

PMID28754664
PMCPMC5584580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.